About Angiocrine Bioscience
Angiocrine Bioscience is a private company based in San Diego, California. It has reported $64,221,795 raised in three offerings on Form D since March 2013. Its chief executive is Paul Finnegan.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2025 | Sep 5, 2025 | $2,100,000of $3.0M target | 16 | $131K | EquityRule 506(b) | Form D ↗ |
| Oct 1, 2021 | Oct 15, 2021 | $58,121,796of $99.3M target | 78 | $745K | EquityRule 506(b) | Form D ↗ |
| Mar 1, 2013 | Mar 13, 2013 | $3,999,999of $4.9M target | 1 | $3.9M | Equity06 | Form D ↗ |
| Total, three offerings | $64,221,795 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Angiocrine Bioscience's Form D filed Sep 5, 2025.
Earlier filings also listed Marc Cohen (director, last listed Oct 2021), Jeff Jonas (director, last listed Oct 2021), Rick Murdock (director, last listed Mar 2013), John Klacking, Ph.D. (executive officer and director, last listed Mar 2013), Jeffrey Port, M.D. (director, last listed Mar 2013), Claude Davis, Ph.D. (secretary and director, last listed Mar 2013) and Brad Daniel (director, last listed Mar 2013).